浙江春禾医药科技

Zhejiang Chunhe Pharmaceutical Technology is a clinical-stage biotechnology company focused on the discovery and development of innovative targeted protein degradation (TPD) drugs. The company leverages its expertise in PROTAC (Proteolysis-Targeting Chimera) and molecular glue technologies to target "undruggable" proteins involved in cancer progression. Its lead program, CH-01, is a novel degrader designed to treat advanced prostate cancer by simultaneously targeting the full-length androgen receptor and its splice variants. Headquartered in Hangzhou, China, the company was founded by a team of seasoned scientists and is backed by prominent venture capital investors. Chunhe aims to provide transformative treatment options for patients with resistant or refractory malignancies.